Board changes

Grahame Cook Named Non-Executive Chairman of Sinclair IS Pharma

Appointment of Stuart Swanson as Non-Executive Director

22 September 2011, Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair IS"), the international specialty pharma company, announces that Board member Grahame Cook will assume the role of Non-Executive Chairman of Sinclair IS effective immediately.

Grahame succeeds John Gregory who has stepped down as Chairman and from the Board of Directors following the successful merger and subsequent integration of Sinclair Pharma with IS Pharma. John joined the Board of IS Pharma in 2000 and played an important role in the successful development of IS Pharma, and latterly the creation of Sinclair IS. He leaves the Company with the best wishes of the Board.

Stuart Swanson, 51, also joins the Board of Directors as Non-Executive Director effective immediately.

Stuart co-founded PharmaSwiss which over the last ten years grew rapidly to become a prominent Eastern Europe specialty pharma company. Stuart was a Board Member and President of Corporate Development prior to leading the company's sale to Valeant Pharmaceuticals in March 2011. Stuart continues to work part-time for Valeant as a consultant.

A fluent Russian speaker, during the 1990s Stuart held a variety of senior positions for Bristol-Myers Squibb and Pfizer, with a focus on the East European region. He is also a co-founder of Hertz Russia and holds a MA from Columbia.

Chris Spooner, Chief Executive of Sinclair IS, said:

"I would like to extend the Board's thanks to John Gregory for his significant contribution throughout the merger process and subsequent integration of Sinclair Pharma with IS Pharma. I am delighted to announce the appointment of Grahame as Chairman and welcome Stuart to the Board. We believe that Stuart's impressive track record in growing European based specialty pharma companies equips him with the requisite experience to provide Sinclair IS with valuable advice and support as we expand our operations internationally."

Save as set out below, there are no further disclosures required under AIM Rule 17 Schedule 2 paragraph (g) in respect of Mr Swanson.

For further information please contact:

Additional disclosures required under AIM Rule 17 Schedule 2 paragraph (g):

Full name: Robert Stuart Swanson

Mr Swanson has a beneficial interest in 1,000,000 ordinary shares of 1p each in the Company, representing 0.3% of the Company's issued share capital.